4//SEC Filing
Thomas Thomas T. 4
Accession 0001385508-21-000136
CIK 0001385508other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:14 PM ET
Size
19.5 KB
Accession
0001385508-21-000136
Insider Transaction Report
Form 4
Thomas Thomas T.
Director
Transactions
- Exercise/Conversion
Common Stock
2021-09-14$10.00/sh+1,500$15,000→ 8,163 total - Sale
Common Stock
2021-09-14$19.06/sh−792$15,096→ 7,371 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-14−25→ 6,834 totalExercise: $10.00Exp: 2021-11-03→ Common Stock (25 underlying) - Exercise/Conversion
Common Stock
2021-09-14$10.00/sh+1,500$15,000→ 8,871 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-14−1,500→ 5,334 totalExercise: $10.00Exp: 2021-11-03→ Common Stock (1,500 underlying) - Exercise/Conversion
Common Stock
2021-09-14$10.00/sh+25$250→ 6,678 total - Sale
Common Stock
2021-09-14$19.70/sh−764$15,051→ 8,107 total - Sale
Common Stock
2021-09-14$18.95/sh−15$284→ 6,663 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-14−1,500→ 3,834 totalExercise: $10.00Exp: 2021-11-03→ Common Stock (1,500 underlying)
Footnotes (6)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- [F2]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 10, after selling to cover the exercise price, will be held by the Reporting Person.
- [F3]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 708, after selling to cover the exercise price, will be held by the Reporting Person.
- [F4]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 736, after selling to cover the exercise price, will be held by the Reporting Person.
- [F5]The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- [F6]On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.
Documents
Issuer
OPIANT PHARMACEUTICALS, INC.
CIK 0001385508
Entity typeother
Related Parties
1- filerCIK 0001689819
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 4:14 PM ET
- Size
- 19.5 KB